Grazia Artioli

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 623 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 456 citations · Full text

Medicine, Gynecology, Oncology +17

Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers

Angela R. Bradbury, Comfort N. Ibe, James J. Dignam et al. · Genetics in Medicine · 2008 · 93 citations · Full text

Medicine, Gynecology, Surgery +8

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial

Domenica Lorusso, Giovanni Scambia, Sandro Pignata et al. · Annals of Oncology · 2015 · 55 citations · Full text

Medicine, Gynecology, Oncology +13

Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness

Vivek Patel, Evan L. Busch, Tara M. Friebel et al. · Cancer Research · 2019 · 52 citations · Full text

Medicine, Genetics, Oncology +17